Celebrex Cardiovascular Safety Trial Will Allow Acetaminophen Use
This article was originally published in The Tan Sheet
Executive Summary
Pfizer believes that allowing patients to take non-NSAID pain relievers, such as acetaminophen, in a trial evaluating the cardiovascular risk profile of Celebrex (celecoxib) will make a long-term placebo-controlled study in the arthritis population feasible